One such example is a Phase III trial combining PD-L1 and MEK inhibition (atezolizumab and cobimetinib) vs. pembrolizumab in advanced BRAFV600 wild-type melanoma (NCT03273153). This evidence concerns the gene CD274 and melanoma.